Plain-English translation of NCT07136792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called pegmolesatide, a long-acting injection given once every 4 weeks to treat anemia (not enough red blood cells) in people with chronic kidney disease on dialysis. Researchers want to see if this medication works well and is safe for patients who are switching from their current anemia treatment.
Many dialysis patients need help making red blood cells, and doctors are looking for longer-acting treatments that require fewer injections. This medication was recently approved, but doctors still need to understand the best way to switch patients from their current treatment to this new medication and what starting doses work best.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication under your skin once every 4 weeks for 12 weeks. Depending on which group you are randomly assigned to, you will receive one of four different starting doses (2 mg, 4 mg, or 6 mg), which may be adjusted based on your blood test results. The study includes a 12-week treatment period followed by 16 weeks of follow-up monitoring, during which you will have regular blood tests to check how well the medication is working and monitor your safety.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China